FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2005489834> ?p ?o ?g. }

• W2005489834 endingPage "748" @default.
• W2005489834 startingPage "741" @default.
• W2005489834 abstract "Kasabach-Merritt syndrome (KMS) is a rare, aggressive, vascular tumor with thrombocytopenia and consumptive coagulopathy. A standard treatment regimen for KMS has not been established. We reviewed our experience of a stepwise approach for the treatment of 10 children with KMS.All patients were first treated with oral corticosteroid (initially 3 mg/kg/day then 5 mg/kg/day) and dipyridamole. Interferon-alpha-2b (IFNalpha2b) was used as second therapy for steroid-resistant cases for 12 months, then tapered to an alternate-day regimen, and then discontinued. Adjunctive therapy, including embolization of the feeding vessel or chemotherapy, was additionally used in patients who failed to respond to IFN or could not be taken off IFN.Ten patients were treated on this protocol with a follow-up time of 1-6 years. Oral corticosteroid plus dipyridamole was successful in four patients, but was tapered off by 12 months without recurrence in only two cases. Of the eight steroid-resistant cases, IFNalpha2b successfully induced regression of the tumor and increased the platelet count in six patients; however, IFNalpha2b was successful as monotherapy in only three cases; two patients died of aspiration pneumonia whilst on therapy and one patient could not be taken off IFNalpha2b until weekly vincristine was given (eight doses). Two other patients did not respond to IFNalpha2b in 4 weeks; embolization and vinblastine was used in one patient to induce regression of the tumor and resolution of thrombocytopenia. Hypertension developed in all children on high-dose prednisolone.KMS may be treated in a stepwise approach. High-dose steroid does not result in a high response rate and is not tolerated well. The response to IFNalpha2b is more favorable, but life-threatening adverse events may occur. Chemotherapy with vincristine or vinblastine may be useful as adjunctive therapy in KMS, but experience is still limited." @default.
• W2005489834 created "2016-06-24" @default.
• W2005489834 creator A5006983023 @default.
• W2005489834 creator A5072256930 @default.
• W2005489834 creator A5081007655 @default.
• W2005489834 date "2003-09-01" @default.
• W2005489834 modified "2023-10-15" @default.
• W2005489834 title "Treatment of Kasabach-Merritt syndrome: a stepwise regimen of prednisolone, dipyridamole, and interferon" @default.
• W2005489834 cites W103592546 @default.
• W2005489834 cites W1523046944 @default.
• W2005489834 cites W1982802846 @default.
• W2005489834 cites W1986369001 @default.
• W2005489834 cites W1990002167 @default.
• W2005489834 cites W2006628947 @default.
• W2005489834 cites W2008577697 @default.
• W2005489834 cites W2009829561 @default.
• W2005489834 cites W2020878317 @default.
• W2005489834 cites W2025729958 @default.
• W2005489834 cites W2027221824 @default.
• W2005489834 cites W2034231683 @default.
• W2005489834 cites W2034930381 @default.
• W2005489834 cites W2039018834 @default.
• W2005489834 cites W2039973874 @default.
• W2005489834 cites W2049705652 @default.
• W2005489834 cites W2050488339 @default.
• W2005489834 cites W2086160188 @default.
• W2005489834 cites W2159948650 @default.
• W2005489834 cites W2168131035 @default.
• W2005489834 cites W2168381797 @default.
• W2005489834 cites W2294534753 @default.
• W2005489834 cites W2340893063 @default.
• W2005489834 cites W4206102891 @default.
• W2005489834 doi "https://doi.org/10.1046/j.1365-4362.2003.01796.x" @default.
• W2005489834 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/12956695" @default.
• W2005489834 hasPublicationYear "2003" @default.
• W2005489834 type Work @default.
• W2005489834 sameAs 2005489834 @default.
• W2005489834 citedByCount "45" @default.
• W2005489834 countsByYear W20054898342012 @default.
• W2005489834 countsByYear W20054898342013 @default.
• W2005489834 countsByYear W20054898342014 @default.
• W2005489834 countsByYear W20054898342015 @default.
• W2005489834 countsByYear W20054898342016 @default.
• W2005489834 countsByYear W20054898342017 @default.
• W2005489834 countsByYear W20054898342018 @default.
• W2005489834 countsByYear W20054898342021 @default.
• W2005489834 countsByYear W20054898342022 @default.
• W2005489834 crossrefType "journal-article" @default.
• W2005489834 hasAuthorship W2005489834A5006983023 @default.
• W2005489834 hasAuthorship W2005489834A5072256930 @default.
• W2005489834 hasAuthorship W2005489834A5081007655 @default.
• W2005489834 hasConcept C126322002 @default.
• W2005489834 hasConcept C141071460 @default.
• W2005489834 hasConcept C2776035437 @default.
• W2005489834 hasConcept C2776694085 @default.
• W2005489834 hasConcept C2776715498 @default.
• W2005489834 hasConcept C2776755627 @default.
• W2005489834 hasConcept C2776804153 @default.
• W2005489834 hasConcept C2776890861 @default.
• W2005489834 hasConcept C2777132456 @default.
• W2005489834 hasConcept C2779401007 @default.
• W2005489834 hasConcept C2779429289 @default.
• W2005489834 hasConcept C2779936836 @default.
• W2005489834 hasConcept C2780372218 @default.
• W2005489834 hasConcept C2781413609 @default.
• W2005489834 hasConcept C71924100 @default.
• W2005489834 hasConcept C90924648 @default.
• W2005489834 hasConceptScore W2005489834C126322002 @default.
• W2005489834 hasConceptScore W2005489834C141071460 @default.
• W2005489834 hasConceptScore W2005489834C2776035437 @default.
• W2005489834 hasConceptScore W2005489834C2776694085 @default.
• W2005489834 hasConceptScore W2005489834C2776715498 @default.
• W2005489834 hasConceptScore W2005489834C2776755627 @default.
• W2005489834 hasConceptScore W2005489834C2776804153 @default.
• W2005489834 hasConceptScore W2005489834C2776890861 @default.
• W2005489834 hasConceptScore W2005489834C2777132456 @default.
• W2005489834 hasConceptScore W2005489834C2779401007 @default.
• W2005489834 hasConceptScore W2005489834C2779429289 @default.
• W2005489834 hasConceptScore W2005489834C2779936836 @default.
• W2005489834 hasConceptScore W2005489834C2780372218 @default.
• W2005489834 hasConceptScore W2005489834C2781413609 @default.
• W2005489834 hasConceptScore W2005489834C71924100 @default.
• W2005489834 hasConceptScore W2005489834C90924648 @default.
• W2005489834 hasIssue "9" @default.
• W2005489834 hasLocation W20054898341 @default.
• W2005489834 hasLocation W20054898342 @default.
• W2005489834 hasOpenAccess W2005489834 @default.
• W2005489834 hasPrimaryLocation W20054898341 @default.
• W2005489834 hasRelatedWork W1984708334 @default.
• W2005489834 hasRelatedWork W2002161524 @default.
• W2005489834 hasRelatedWork W2003257383 @default.
• W2005489834 hasRelatedWork W2020619947 @default.
• W2005489834 hasRelatedWork W2035384358 @default.
• W2005489834 hasRelatedWork W2163470360 @default.
• W2005489834 hasRelatedWork W2167328209 @default.
• W2005489834 hasRelatedWork W3157798126 @default.
• W2005489834 hasRelatedWork W4251122529 @default.
• W2005489834 hasRelatedWork W4294904111 @default.

• next